Taimei Technology completed Series E and Series E+ rounds at $212m.

Taimei Technology, a Chinese cloud-based software provider that serves pharmaceutical companies and clinical research organizations, completed Series E and Series E+ rounds of financing at $212m. Taimei Technology operates as a technology solution provider in the field of life sciences with a focus on clinical research and pharmacovigilance, which is also known as drug safety, is related to the collection, detection, assessment, monitoring, and prevention of adverse effects of pharmaceutical products.